62.54Open62.54Pre Close0 Volume11 Open Interest170.00Strike Price0.00Turnover6383.69%IV-5.58%PremiumJan 17, 2025Expiry Date76.27Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9944Delta0.0004Gamma3.22Leverage Ratio-128.2884Theta0.0000Rho3.20Eff Leverage0.0001Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet